IV 

111TH CONGRESS 

2D SESSION H. RES. 1140 

Commending the progress made by anti-tuberculosis programs. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 4, 2010 

Mr. ENGEL (for himself, Mr. POE of Texas, Mr. GENE GREEN of Texas, Mr. 

PAYNE, Ms. LEE of California, Ms. BALDWIN, Mr. DOYLE, Ms. MATSUI, 

Mr. NADLER of New York, Mrs. MALONEY, Ms. SCHAKOWSKY, Mr. 

SMITH of Washington, and Mr. CROWLEY) submitted the following resolution; which was referred to the Committee on Foreign Affairs, and in 

addition to the Committee on Energy and Commerce, for a period to be 

subsequently determined by the Speaker, in each case for consideration 

of such provisions as fall within the jurisdiction of the committee concerned 

RESOLUTION 

Commending the progress made by anti-tuberculosis 

programs. 

Whereas tuberculosis (hereafter in this preamble referred to 

as ‘‘TB’’) is the second leading global infectious disease 

killer behind HIV/AIDS, claiming 1,800,000 million lives 

each year; 

Whereas the global TB pandemic and the spread of drug resistant TB present a persistent public health threat to 

the United States; 

Whereas according to 2009 data of the World Health Organization, 5 percent of all new TB cases are drug resistant; 


jbell on DSKDVH8Z91PROD with BILLS
2 

•HRES 1140 IH 

Whereas TB is the leading killer of people with HIV/AIDS; 

Whereas TB is the third leading killer of adult women, and 

the stigma associated with TB disproportionately affects 

women, causing them to delay seeking care and interfering with treatment adherence; 

Whereas the Institute of Medicine (IOM) found that the resurgence of TB between 1980 and 1992 was caused by 

cuts in TB control funding and the spread of HIV/AIDS; 

Whereas, although the numbers of TB cases in the United 

States continue to decline, progress towards TB elimination has slowed, and it is a disease that does not recognize borders; 

Whereas New York City had to spend over $1,000,000,000 

to control a multi-drug resistant TB outbreak between 

1989 and 1993; 

Whereas an extensively drug resistant form of TB, known as 

XDR–TB (hereafter referred to in this preamble as 

‘‘XDR–TB)’’), is very difficult and expensive to treat and 

has high and rapid fatality rates, especially among HIV/ 

AIDS patients; 

Whereas the United States has had more than 83 cases of 

XDR–TB over the last decade; 

Whereas the Centers for Disease Control and Prevention estimated in 2009 that it costs $483,000 to treat a single 

case of XDR–TB; 

Whereas African-Americans are 8 times more likely to have 

TB than Caucasians, and significant disparities exist 

among other United States minorities, including Native 

Americans, Asian-Americans, and Hispanic Americans; 


jbell on DSKDVH8Z91PROD with BILLS
3 

•HRES 1140 IH 

Whereas the United States public health system has the expertise to eliminate TB, but many State TB programs 

have been left seriously under-resourced due to budget 

cuts at a time when TB cases are growing more complex 

to diagnose and treat; 

Whereas, although drugs, diagnostics and vaccines for TB 

exist, these technologies are antiquated and are increasingly inadequate for controlling the global epidemic; 

Whereas the most commonly used TB diagnostic in the 

world, sputum microscopy, is more than 100 years old 

and lacks sensitivity to detect TB in most HIV/AIDS patients and in children; 

Whereas current tests to detect drug resistance take at least 

1 month to complete and faster drug susceptibility tests 

must be developed to stop the spread of drug resistant 

TB; 

Whereas the TB vaccine, BCG, provides some protection to 

children, but has little or no efficacy in preventing pulmonary TB in adults; 

Whereas there is also a critical need for new TB drugs that 

can safely be taken concurrently with antiretroviral therapy for HIV; 

Whereas the Global Health Initiative commits to reducing TB 

prevalence by 50 percent through 2015; 

Whereas enactment of the Lantos-Hyde Global Leadership 

Against HIV/AIDS, TB and Malaria Act and the Comprehensive TB Elimination Act provide an historic 

United States commitment to the global eradication of 

TB, including to the successful treatment of 4,500,000 

new TB patients and 90,000 new multi-drug resistant 


jbell on DSKDVH8Z91PROD with BILLS
4 

•HRES 1140 IH 

(MDR) TB cases by 2013, while providing additional 

treatment through coordinated multilateral efforts; 

Whereas the United States Agency for International Development provides financial and technical assistance to nearly 

40 highly burdened TB countries and supports the development of new diagnostic and treatment tools, and is authorized to support research to develop new vaccines to 

combat TB; 

Whereas the Centers for Disease Control and Prevention, 

working in partnership with States and territories of the 

United States, directs the national TB elimination program and essential national TB surveillance, technical assistance, prevention activities and supports the development of new diagnostic, treatment and prevention tools 

to combat TB; 

Whereas the National Institutes of Health, through its many 

institutes and centers, plays the leading role in basic and 

clinical research into the identification, treatment and 

prevention of TB; and 

Whereas the Global Fund to Fight AIDS, Tuberculosis and 

Malaria provides 63 percent of all international financing 

for TB programs worldwide and finances proposals worth 

$3,200,000,000 in 112 countries, and TB treatment for 

6,000,000 and HIV/TB services for 1,800,000, and in 

many countries in which the Global Fund supports programs, TB prevalence is declining, as are TB mortality 

rates: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) commends the progress made by anti-tuber3 culosis programs, including the U.S. Agency for 

4 International Development, the Centers for Disease 


jbell on DSKDVH8Z91PROD with BILLS
5 

•HRES 1140 IH 

1 Control and Prevention and the Global Fund to 

2 Fight AIDS, Tuberculosis and Malaria; and 

3 (2) reaffirms its commitment to global tuber4 culosis control made through the Lantos-Hyde U.S. 

5 Leadership Against HIV/AIDS, Tuberculosis and 

6 Malaria Act of 2008. 

Æ 


jbell on DSKDVH8Z91PROD with BILLS